While semaglutide was initially used to treat type 2 diabetes, weight loss was found to be a positive side effect of treatment
It was only when he saw that a study of 17,000 patients by Harvard Medical School concluded that patients who were prescribed semaglutide had a higher incidence of developing NAION than those who were not taking the drug
Statistics from the phase 3 SURMOUNT study, which recruited over 5,000 adults globally, demonstrated a pronounced reduction in body weight in the tirzepatide-treated group compared to placebo (NCT04184622)
This mimics your bodys natural rhythm of growth hormone release often referred to as biological GH mimicry. Ipamorelin promotes a controlled growth hormone pulse, without significant stimulation of hunger or adrenal axis disruption, making it superior to earlier GHRP compounds. Patel et al., Endocrine Reviews Unlike exogenous human growth hormone (HGH) , which suppresses natural production over time, Ipamorelin does not cause negative feedback loop suppression
This is where alternatives like peptide therapies start entering the conversation